

chain nodes :

23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

23-24 24-25 26-28 27-28 29-30 31-32 32-33 34-35 36-37 37-38

ring bonds :

1-2 1-5 2-3 3-4 3-6 4-5 4-9 6-7 6-13 6-16 7-8 7-10 8-9 8-12
10-11 11-12 13-14 14-15 15-16

exact/norm bonds :

1-2 1-5 2-3 3-4 3-6 4-5 4-9 6-7 6-13 6-16 7-8 7-10 8-9 8-12
10-11 11-12 13-14 14-15 15-16 23-24 24-25 26-28 27-28 29-30
31-32 32-33 34-35 36-37 37-38

G1:C,O,S,N

G2:CH2,CH, [*1-*2], [*3-*4], [*5-*6], [*7-*8], [*9-*10], [*11-*12]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 23:CLASS
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS

09/868,535

=> d his

(FILE 'HOME' ENTERED AT 14:13:11 ON 09 SEP 2002)

L1 FILE 'CAPLUS' ENTERED AT 14:13:18 ON 09 SEP 2002
1 S WO200037470/PN
SELECT RN L1 1

L2 FILE 'REGISTRY' ENTERED AT 14:13:38 ON 09 SEP 2002
97 S E1-97

L3 FILE 'CAPLUS' ENTERED AT 14:13:49 ON 09 SEP 2002
1 S L1 AND L2

FILE 'STNGUIDE' ENTERED AT 14:14:34 ON 09 SEP 2002

L4 FILE 'REGISTRY' ENTERED AT 14:22:52 ON 09 SEP 2002
STRUCTURE UPLOADED
L5 QUE L4
L6 5 S L5
L7 79 S L4 SSS FUL

L8 FILE 'CAPLUS' ENTERED AT 14:24:26 ON 09 SEP 2002
3 S L7

=> d bib abs hitstr 1-3

X
 IB ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
 IN 2001:319725 CAPLUS
 DN 134:320888
 TI Use of substance P antagonists for influencing the circadian timing system
 IN Dugovic, Christine Jeanne; Janssens, Frans Eduard
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030348	A1	20010503	WO 2000-EP10201	20001016
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI EP 1999-203499 A 19991025

OS MARPAT 134:320888

AB The invention concerns the use of N-contg. heterocyclic derivs. (Markush included) in the manuf. of medicaments useful for beneficially influencing the circadian timing system or enhancing the sleep efficiency of a mammal, suitably a human being. The compds. of the invention are described in full in WO 97/16440, WO 97/14324, WO 97/24350, and WO 97/24356.

IT **336790-73-9 336790-73-9D**, N-oxides and stereoisomers
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substance P antagonists for influencing circadian timing system)

RN 336790-73-9 CAPLUS

CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-2-(phenylmethyl)-(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 336790-73-9 CAPLUS

CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-2-(phenylmethyl)-(9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:441796 CAPLUS
 DN 133:74016
 TI preparation of spirotricyclic compounds as H1 receptor antagonists
 IN Janssens, Frans Eduard; Leenaerts, Joseph Elisabeth
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

 PI WO 2000037470 A1 20000629 WO 1999-EP10176 19991215
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 BR 9916371 A 20010918 BR 1999-16371 19991215
 EP 1144411 A1 20011017 EP 1999-964625 19991215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 NO 2001002710 A 20010601 NO 2001-2710 20010601
 PRAI EP 1998-204347 A 19981219
 WO 1999-EP10176 W 19991215
 OS MARPAT 133:74016
 GI



AB Title compds. [I; R = Z2Z3R5, Z2NHCOR5, Z2R5; R1 = H, halo, alkyl, acyl, etc.; R2 = H, halo, alkyl, aryl, etc.; R3R4 = YCH:CH, CH:CHY, CH:CHCH:CH; R5 = (un)substituted heteroaryl, -tetrahydrofuranyl, etc.; Y = O, S, (alkyl)imino, alkanoylimino; Z = alkylene, CH:CH, CH2CH(OH), CH2O, etc.; Z1 = CH2 or CH2CH2; Z3 = O, S, NH] were prepd. Thus, 1-phenylmethyl-1H-imidazole was condensed with 1-phenylmethyl-4-piperidone and the product cyclized to give, after hydrogenation, I (R1 = R2 = H, R3R4 = CH:CHCH:CH, Z = CH2, Z1 = CH2CH2) (II; R = H) which was N-alkylated by 1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one to give II [R = 2-(4-ethyl-5-oxo-1,4-dihydro-1H-tetrazol-1-yl)ethyl]. Data for biol. activity of I were given.

IT 279253-41-7P 279253-83-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of spirotricyclic compds. as H1 receptor antagonists)

RN 279253-41-7 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic acid, 3-(aminocarbonyl)-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-83-7 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide, 5,6-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 193469-39-5P 194158-03-7P 279252-93-6P

279252-95-8P 279252-98-1P 279253-00-8P

279253-03-1P 279253-05-3P 279253-07-5P

279253-09-7P 279253-11-1P 279253-13-3P

279253-15-5P 279253-17-7P 279253-19-9P

279253-21-3P 279253-23-5P 279253-25-7P

279253-27-9P 279253-29-1P 279253-31-5P

279253-33-7P 279253-35-9P 279253-37-1P

279253-39-3P 279253-43-9P 279253-45-1P

279253-48-4P 279253-51-9P 279253-53-1P

279253-55-3P 279253-58-6P 279253-60-0P

279253-63-3P 279253-66-6P 279253-69-9P

279253-71-3P 279253-74-6P 279253-77-9P

279253-79-1P 279253-84-8P 279253-85-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of spirotricyclic compds. as H1 receptor antagonists)

RN 193469-39-5 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 194158-03-7 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279252-93-6 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-methanol, 5,6-dihydro- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279252-95-8 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-methanol, 5,6-dihydro-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 279252-93-6

CMF C17 H21 N3 O

09/868,535

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 279252-98-1 CAPLUS

CN Sulfamic acid, cyclohexyl-, compd. with 5,6-dihydro-1'-methylspiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 279252-97-0


CMF C17 H21 N3

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 100-88-9

CMF C6 H13 N O3 S



RN 279253-00-8 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 1'-butyl-5,6-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-03-1 CAPLUS

CN Sulfamic acid, cyclohexyl-, compd. with 1'-[3-(4-fluorophenoxy)propyl]-5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 279253-02-0


CMF C25 H28 F N3 O

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

09/868,535

CRN 100-88-9
CMF C6 H13 N O3 S



RN 279253-05-3 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
5,6-dihydro-1'-(3-methyl-2-butenyl)-, monohydriodide (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-07-5 CAPLUS
CN 5H-Tetrazol-5-one, 1-[2-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-
11,4'-piperidin]-1'-yl)ethyl]-4-ethyl-1,4-dihydro-, dihydrochloride (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-09-7 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-acetonitrile,
5,6-dihydro- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-11-1 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic
acid, 5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-13-3 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with 5,6-dihydro-1'-[(tetrahydro-2-
furanyl)methyl]spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]
(2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 279253-12-2
CMF C21 H27 N3 O

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 100-88-9
CMF C6 H13 N O3 S



RN 279253-15-5 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with 5,6-dihydro-1'-(2-

thienylmethyl) spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]
(1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 279253-14-4
CMF C21 H23 N3 S

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 100-88-9
CMF C6 H13 N O3 S



RN 279253-17-7 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-propanoic
acid, 3-(aminocarbonyl)-5,6-dihydro-, methyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-19-9 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide,
5,6-dihydro-1'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-21-3 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-acetic acid,
3-(aminocarbonyl)-5,6-dihydro-, methyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-23-5 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-propanoic
acid, 3-(aminocarbonyl)-5,6-dihydro-.alpha.-phenyl-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-25-7 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide,
1'-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-5,6-dihydro- (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-27-9 CAPLUS
CN Carbamic acid, [2-[3-(aminocarbonyl)-5,6-dihydrospiro[11H-imidazo[2,1-
b][3]benzazepine-11,4'-piperidin]-1'-yl]ethyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-29-1 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide,
1'-(2-aminoethyl)-5,6-dihydro- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-31-5 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic acid, 3-(aminocarbonyl)-5,6-dihydro-, methyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-33-7 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide, 5,6-dihydro-1'-methyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-35-9 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic acid, 2,3-dibromo-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-37-1 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic acid, 2,3-bis(aminocarbonyl)-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-39-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic acid, 3-chloro-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-43-9 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-6(5H)-one, 1'-methyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-45-1 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-6(5H)-one, 1'-methyl-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 279253-43-9

CMF C17 H19 N3 O

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



09/868,535

RN 279253-48-4 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-6(5H)-one,
(2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 279253-47-3
CMF C16 H17 N3 O

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 279253-51-9 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 194158-03-7
CMF C16 H17 N3

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 279253-53-1 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
5,6-dihydro-2,3-bis(methoxymethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-55-3 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-ethanamine,
5,6-dihydro-, trihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-58-6 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-ethanamine,

5,6-dihydro-N-2-pyrimidinyl-, trihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-60-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[2-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)ethyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-63-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 3-chloro-5,6-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 279253-62-2

CMF C16 H18 Cl N3

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 279253-66-6 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-2,3-dicarboxamide, 5,6-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-69-9 CAPLUS


CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-3-(methoxymethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-71-3 CAPLUS


CN Spiro[4H-azepine-4,11'-[11H]imidazo[2,1-b][3]benzazepine], 1,2,3,5,5',6,6',7-octahydro-, monohydrochloride (9CI) (CA INDEX NAME)

09/868,535



● HCl

RN 279253-74-6 CAPLUS
CN Spiro[4H-azepine-4,11'-[11H]imidazo[2,1-b][3]benzazepine],
1,2,3,5,5',6,6',7-octahydro-1-methyl- (9CI) (CA INDEX NAME)



RN 279253-77-9 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)ethyl]-7-methyl-, trihydrochloride
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-79-1 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-84-8 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
1'-butyl-5,6-dihydro- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-85-9 CAPLUS
CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
5,6-dihydro-3-(methoxymethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 279253-69-9
CMF C18 H23 N3 O

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



IT 193469-37-3P 193469-45-3P 279253-47-3P
 279253-87-1P 279253-88-2P 279253-89-3P
 279253-90-6P 279253-91-7P 279253-92-8P
 279253-93-9P 279253-94-0P 279253-95-1P
 279253-96-2P 279254-07-8P 279254-08-9P
 279254-09-0P 279254-10-3P 279254-11-4P
 279254-12-5P 279254-13-6P 279254-14-7P
 279254-15-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(prepn. of spirotricyclic compds. as H1 receptor antagonists)

RN 193469-37-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
 5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 193469-45-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-
 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 279253-47-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-6(5H)-one (9CI)
 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-87-1 CAPLUS

CN Spiro[imidazo[1,2-b]isoquinoline-10(5H),4'-piperidine],
 1'-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 279253-88-2 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
 3-bromo-5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-89-3 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine],
 3-bromo-5,6-dihydro-1'-(phenylmethyl)-, (2E)-2-butenedioate (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 279253-88-2
 CMF C23 H24 Br N3

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 110-17-8
 CMF C4 H4 O4
 CDES 2:E

Double bond geometry as shown.



RN 279253-90-6 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide,
 5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-91-7 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-methanol,
 5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-92-8 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxaldehyde,
 5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-93-9 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-methanamine,
5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-94-0 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-methanamine,
5,6-dihydro-1'-(phenylmethyl)-, trihydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-95-1 CAPLUS

CN Urea, [[5,6-dihydro-1'-(phenylmethyl)spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-3-yl]methyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279253-96-2 CAPLUS

CN Methanesulfonamide, N-[[5,6-dihydro-1'-(phenylmethyl)spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-3-yl]methyl]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-07-8 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-8,9-diol,
5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-08-9 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic
acid, 6-[(ethoxycarbonyl)oxy]-, ethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-09-0 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic
acid, 5,6-dihydro-, ethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-10-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic
acid, 5,6-dihydro-3-(hydroxymethyl)-, ethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-11-4 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic
acid, 3-formyl-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-12-5 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1',3-dicarboxylic
acid, 5,6-dihydro-, 1'-(1,1-dimethylethyl) 3-methyl ester (9CI) (CA INDEX
NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-13-6 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1',3-dicarboxylic
acid, 5,6-dihydro-, 1'-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

09/868,535

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-14-7 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-carboxylic
acid, 3-bromo-5,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 279254-15-8 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-6-ol, 5,6-dihydro-
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:499057 CAPLUS
 DN 127:149145
 TI 1-(1,2-Disubstituted piperidiny1)-4-(fused imidazole)piperidine
 derivatives useful as substance P antagonists
 IN Janssens, Frans Eduard; Lunaerts, Joseph E.; Van Roosbroeck, Yves E. M.
 PA Jansseen Pharmaceutica N. V., Belg.
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724356	A1	19970710	WO 1996-EP5885	19961220
	W: AL, AM, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, BF, BJ, CF, CG, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	TW 382017	B	20000211	TW 1996-85115390	19961213
	CA 2238817	AA	19970710	CA 1996-2238817	19961220
	AU 9713086	A1	19970728	AU 1997-13086	19961220
	AU 716071	B2	20000217		
	EP 843679	A1	19980527	EP 1996-944693	19961220
	EP 843679	B1	20011107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
	CN 1206417	A	19990127	CN 1996-199396	19961220
	CN 1066733	B	20010606		
	BR 9612307	A	19990713	BR 1996-12307	19961220
	JP 2000506503	T2	20000530	JP 1997-524033	19961220
	AT 208392	E	20011115	AT 1996-944693	19961220
	ES 2167619	T3	20020516	ES 1996-944693	19961220
	ZA 9610889	A	19980623	ZA 1996-10889	19961223
	NO 9802405	A	19980819	NO 1998-2405	19980527
	US 6251894	B1	20010626	US 1998-102136	19980622
PRAI	EP 1995-203652	A	19951227		
	WO 1996-EP5885	W	19961220		
OS	MARPAT 127:149145				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns compds. I and their N-oxides, pharmaceutically acceptable addn. salts, and stereoisomers [wherein n = 0, 1, or 2; m = 1 or 2, provided that if m = 2, then n = 1; Q = O or NR₃; X = bond, O, S, or NR₃; R₁ = Ar₁, Ar₁-alkyl, or di-Ar₁-alkyl, wherein each alkyl group is optionally substituted; R₂ = Ar₂, Ar₂-alkyl, Het, Het-alkyl; R₃ = H or alkyl; L = piperidine group Q₁ or spiropiperidine group Q₂; Ar₁ = (un)substituted Ph; Ar₂ = naphthalenyl, (un)substituted Ph; Het = (un)substituted mono- or bicyclic heterocycle; AB = atoms to form (un)substituted benzo or certain 5-membered hetero fusions; dotted line = optional pi bond; Z = CH₂, CH₂CH₂, CH:CH, CH₂CH(OH), CH₂O, CH₂CO,

CH₂C(:NOH), with provisos; R₄ = H, alkyl, halo, carboxyalkyl, etc.; R₅ = H, alkyl, hydroxyalkyl, Ar₁, halo; or R₄R₅ = CH:CHCH:CH, (CH₂)₄; R₆ = H, alkyl, Ar₁-alkyl]. I are substance P antagonists, and are useful for treating a variety of conditions, esp. pain, emesis, or asthma. For instance, reductive amination of 1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-4-piperidinone with 6,11-dihydro-11-(4-piperidinylene)-5H-imidazo[2,1-b][3]benzazepine, by hydrogenation in the presence of a thiophene-poisoned Pd/C catalyst, gave title compd. II. In a test for antagonism of substance P-induced relaxation of isolated pig coronary arteries, I gave up to 100% inhibition at 3 .times. 10⁻⁹ M.

IT **193469-37-3P 193469-38-4P 193469-39-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of piperidinyl(fused imidazole)piperidine derivs. as substance P antagonists)
 RN 193469-37-3 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 193469-38-4 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-1'-(phenylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 193469-37-3
 CMF C23 H25 N3

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 110-17-8
 CMF C4 H4 O4
 CDES 2:E

Double bond geometry as shown.



RN 193469-39-5 CAPLUS
 CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **193469-20-4P 193469-21-5P 193469-23-7P**
193469-24-8P 193469-25-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of piperidinyl(fused imidazole)piperidine derivs. as substance P antagonists)

RN 193469-20-4 CAPLUS
 CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(5,6-dihydrospiro[11H-

imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-2-(phenylmethyl)-,
cis- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 193469-21-5 CAPLUS

CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-2-(phenylmethyl)-,
trans- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 193469-23-7 CAPLUS

CN Piperidine, 4-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-, cis- (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 193469-24-8 CAPLUS

CN Piperidine, 4-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-, trans- (9CI)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 193469-25-9 CAPLUS

CN Piperidine, 4-(5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidin]-1'-yl)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **193469-45-3**

RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of piperidinyl(fused imidazole)piperidine
derivs. as substance P antagonists)

RN 193469-45-3 CAPLUS

CN Spiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine], 5,6-dihydro-
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***